Document is current

Article History

Received: 24 June 2019

Accepted: 7 July 2020

First Online: 31 July 2020

Competing interests

: P. Ribó has received honoraria from LETIPharma, AstraZeneca, Allergy Therapeutics, and Diater. J. Molina. states that for the past 3 years he has received fees for drafting documents, being on board an expert committee, and lectures from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Menarini, Novartis, Orion Pharma, Pfizer, Roche, semFYC, SOMAMFYC and SERMAS. He has received funding for research projects from different government agencies, from scientific societies, as well as from Boehringer-Ingelheim, AstraZeneca, Chiesi, and Novartis, and is a consultant for AstraZeneca and Sanofi. M. Calle. has received speaker fees from Boehringer Ingelheim, AstraZeneca, GlaxoSmithKline, Menarini, and Novartis and has received consulting fees from GlaxoSmithKline, Gebro Pharma, and Novartis. L.M. has participated in advisory and training activities for Zambon, Esteve, Orion Pharma, GSK, TEVA, and ROVI. C.C. and P. Rytilä are employed by Orion Pharma. V.P. previously received honoraria for speaking at sponsored meetings by AstraZeneca, Chiesi, GlaxoSmithKline and Novartis. He also received assistance in traveling to meetings from Chiesi and Novartis. He acted as a consultant for ALK, AstraZeneca, Boehringer, MundiPharma, and Sanofi. He has also received funding/grant support for research projects from a variety of government agencies and not-for-profit foundations, as well as AstraZeneca, Chiesi, and Menarini. A.V. has previously received honoraria for speaking at sponsored meetings by AstraZeneca, Chiesi, and Novartis and is a consultant for AstraZeneca and Sanofi.